Global 3D Bioprinting Market to Grow at a CAGR of more than 25% by 2021

Renewable energy

The global 3D bioprinting market is currently valued at almost USD 1,355 million and is expected to surpass USD 3,436 million by 2021, says Technavio.

Technavio has announced its latest market research report on the global 3D bioprinting market, under its embedded systems portfolio. This market analysis discusses the major drivers and key emerging trends and offers an analysis of key vendors like 3D Bioprinting Solutions, 3D Biotek, and Advanced BioMatrix.

According to Sunil Kumar Singh, a lead analyst for embedded systems research at Technavio, “3D bioprinters are generally more complex and difficult to procure when compared to conventional printers. However, the prices of the 3D bioprinters are witnessing a steep decline owing to the emergence of new players in the market space. These vendors are providing low-cost 3D bioprinters to low-budget research organizations, laboratories, and universities.”

BioBots offers a beta version of their 3D bioprinter called the BioBot 1 for USD 10,000, but the prices can come down to USD 5,000 provided the end-user helps or shares in the process of developing the bioprinter. Another startup named Aether offers 3D bioprinter at the price of USD 9,000; CELLINK provides a 3D bioprinter called INKREDIBLE at a retail price of USD 5,000, which also uses a syringe-based extrusion technology for the bioprinting process.

Click here to request a free sample of this report

Developments in scaffold-free bioprinting

Vendors like Regenova have developed a methodology that puts 3D macroscopic tissue cells onto the microscopic needle array by placing one tissue cell onto the other and creating a structure called cell spheroids. These spheroids are later removed from the needle array and placed in the culture cabinet for further development. Through this method of 3D bioprinting, called the Kenzan method, many configurations of cells can be made, which includes human and animal tissue bioprinting.

Collaboration among the end-users for knowledge sharing purposes

Currently, the end-users of 3D bioprinters are mostly limited to research organizations, bioengineering laboratories, and universities. In April 2016, the Italian Regenerative Medicine Infrastructure (IRMI) initiated the setting up of advanced infrastructure in the European region to ensure sharing of knowledge and 3D bioprinting technologies among different disciplines in the genre of regenerative medicine. The need for such collaborations rises from the complexities associated with the field of bio-engineering and 3D bioprinting.

This research report includes an in-depth analysis and market shares and sizes of the sub-segments and geography. An analysis of the key companies, including their market shares, business overview, key financials, etc. is provided in this study. This market study also provides a detailed analysis of key drivers, challenges, and opportunities influencing this market.

A more detailed analysis is available in the Technavio report titled, ‘Global 3D Bioprinting Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.

Other related reports:

To read more press releases click here